Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study

Clinical Therapeutics

Volumn 22, Issue 5, 2000, Pages 583-599

  Sacristán, José A ^a,e   Gómez, Juan Carlos ^a   Montejo, Angel Luis ^b   Vieta, Eduardo ^c   Gregor, Karl J ^d  

^a DCRandT   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e ELI LILLY AND COMPANY   (Spain)

Author keywords

Antipsychotics; Dosing; Haloperidol; Observ ational study; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; AMENORRHEA; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTONIA; PHARMACOEPIDEMIOLOGY; PROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SOMNOLENCE; TREATMENT OUTCOME; TREMOR;

EID: 0033935150     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80046-6     Document Type: Article

References (26)

1. 1. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345:1616-1619.
2. 2. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J. 1998; 317:1181-1184.
3. 3. Lasagna L. A plea for the "naturalistic" study of medicines. Eur J Clin Pharmacol. 1974;7:153-154. Editorial.
4. 4. Buckley PF. Substance abuse in schizophrenia: A review. J Clin Psychiatry. 1998;59(Suppl 3):26-30.
5. 5. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva, Switzerland: World Health Organization; 1994.
6. 6. Gómez JC, Sacristán JA, Hernandez J, et al. The safety of olanzapine compared to other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry. 2000;61:335-343.
7. 7. COSTART. Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, Md: US Department of Health and Human Services; 2000;61:335-343.
8. 8. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
9. 9. Clinical global impressions. In: Guy E, ed. ECDEU Assessment for Psychopharmacology. Rev. ed. Rockville, Md: National Institute of Mental Health; 1976.
10. 10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994.
11. 11. Chouinard G, Kopala L, Labelle A, et al. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. Can J Psychiatry. 1998;43:1018-1025.
12. 12. Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. Psychiatr Serv. 1999;50:163-168.
13. 13. Sacristán JA, Soto J. Drug utilisation studies as tools in health economics. Pharmacoeconomics. 1994;5:299-312.
14. 14. Zyprexa® [package insert]. Indianapolis, Ind: Eli Lilly and Company; 1998.
15. 15. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
16. 16. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-137.
17. 17. Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172:499-505.
18. 18. Kasper S. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol. 1998;13:253-262.
19. 19. Risperdal® [package insert]. Titusville, NJ: Janssen Pharmaceutica; 1999.
20. 20. Peuskens J, and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712-726.
21. 21. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
22. 22. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
23. 23. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253-273.
24. 24. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
25. 25. Tollefson G, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
26. 26. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.